ValuEngine upgraded shares of Cue Biopharma (NASDAQ:CUE) from a hold rating to a buy rating in a report issued on Thursday morning, ValuEngine reports.
Separately, Robert W. Baird began coverage on Cue Biopharma in a research note on Thursday, July 25th. They issued an outperform rating and a $13.00 price objective for the company.
Shares of Cue Biopharma stock traded down $0.02 on Thursday, hitting $8.17. The company had a trading volume of 76,913 shares, compared to its average volume of 126,805. The firm has a market capitalization of $170.21 million, a PE ratio of -4.21 and a beta of 1.21. Cue Biopharma has a 1 year low of $4.16 and a 1 year high of $9.94. The stock’s 50 day simple moving average is $7.68. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.02 and a quick ratio of 3.02.
Cue Biopharma (NASDAQ:CUE) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.54) EPS for the quarter. The company had revenue of $0.37 million during the quarter. Cue Biopharma had a negative return on equity of 116.05% and a negative net margin of 3,233.51%. As a group, analysts anticipate that Cue Biopharma will post -2.23 EPS for the current year.
In other Cue Biopharma news, SVP Colin Sandercock purchased 16,938 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The stock was bought at an average cost of $7.83 per share, with a total value of $132,624.54. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders bought 21,315 shares of company stock valued at $163,322. Company insiders own 16.80% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the stock. BNP Paribas Arbitrage SA increased its position in shares of Cue Biopharma by 1,159.9% during the first quarter. BNP Paribas Arbitrage SA now owns 3,805 shares of the company’s stock valued at $29,000 after acquiring an additional 3,503 shares during the last quarter. Strs Ohio grew its holdings in Cue Biopharma by 500.0% during the second quarter. Strs Ohio now owns 15,000 shares of the company’s stock valued at $134,000 after purchasing an additional 12,500 shares during the period. Sigma Planning Corp bought a new position in Cue Biopharma during the first quarter valued at $325,000. Bank of New York Mellon Corp grew its holdings in Cue Biopharma by 16.3% during the fourth quarter. Bank of New York Mellon Corp now owns 51,776 shares of the company’s stock valued at $243,000 after purchasing an additional 7,272 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Cue Biopharma by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 130,961 shares of the company’s stock valued at $615,000 after purchasing an additional 14,923 shares during the period. 16.62% of the stock is owned by institutional investors.
Cue Biopharma Company Profile
Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.
Recommended Story: Options Trading – Understanding Strike Price
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.